1). It is now well established that antibodies that block the interaction between PD-1 on T cells and PD-L1 on tumor cells can boost T cell activity and proliferation, leading to enhanced ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Patients previously treated with PD-1 blockers showed favorable responses, with 80% having stable disease or better as their best response. Disclaimer: This is an AI-generated summary of a press ...

1). It is now well established that antibodies that block the interaction between PD-1 on T cells and PD-L1 on tumor cells can boost T cell activity and proliferation, leading to enhanced ...